Eton Pharmaceuticals, Inc. (NASDAQ:ETON) shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's forecasts. The analysts greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals. Eton Pharmaceuticals has also found favour with investors, with the stock up a magnificent 30% to US$61.45 over the past week. We'll be curious to see if these new estimates convince the market to lift the stock price higher still.
After this upgrade, Eton Pharmaceuticals' four analysts are now forecasting revenues of US$287m in 2027. This would be a major 103% improvement in sales compared to the last 12 months. Statutory earnings per share are presumed to jump 67% to US$2.90. Previously, the analysts had been modelling revenues of US$220m and earnings per share (EPS) of US$2.09 in 2027. There has definitely been an improvement in perception recently, with the analysts substantially increasing both their earnings and revenue estimates.
See our latest analysis for Eton Pharmaceuticals
With these upgrades, we're not surprised to see that the analysts have lifted their price target 13% to US$80.75 per share.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Eton Pharmaceuticals' past performance and to peers in the same industry. It's clear from the latest estimates that Eton Pharmaceuticals' rate of growth is expected to accelerate meaningfully, with the forecast 76% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 42% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 8.7% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Eton Pharmaceuticals is expected to grow much faster than its industry.
The Bottom Line
The biggest takeaway for us from these new estimates is that analysts upgraded their earnings per share estimates, with improved earnings power expected for next year. They also upgraded their revenue estimates for next year, and sales are expected to grow faster than the wider market. With a serious upgrade to expectations and a rising price target, it might be time to take another look at Eton Pharmaceuticals.
These earnings upgrades look like a sterling endorsement, but before diving in - you should know that we've spotted 3 potential concern with Eton Pharmaceuticals, including concerns around earnings quality. For more information, you can click through to our platform to learn more about this and the 1 other concern we've identified .
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.